Prothena to Report Third Quarter 2026 Financial Results on November 5
Business Wire•29/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 and nine-month 2026 results scheduled for November 5 after U.S. market close
- ➤Prothena will not conduct a conference call alongside the results release
- ➤Prothena pipeline targets Parkinson’s, ATTR amyloidosis, Alzheimer’s disease and ALS
Expert Statements
Mark Johnson, Senior Vice President, Head of Investor Relations and Corporate Communications at Prothena
“Mark Johnson, CFA”
Prothena to Report Third Quarter 2026 Financial Results on November 5
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its third quarter and first nine months of 2026 financial results on Thursday, November 5, 2026, after the close of the U.S. financial markets.
Get started
Create a free account to read the full story.